WASHINGTON (dpa-AFX) - BioSante Pharmaceuticals, Inc. (BPAX) announced that data from studies of the Pill-Plus 'triple component' oral contraceptive were presented on March 10, 2012 by Pantarhei Bioscience at the World Congress of Gynecological Endocrinology in Florence, Italy.
The company noted that to date, six prospective, randomized controlled Phase II clinical studies of the Pill-Plus have been completed in 355 subjects. In these studies, use of the Pill-Plus has been shown to increase frequency of sexual activity, arousal, responsiveness to partner, genital sensations and vaginal lubrication. Besides, improvements were seen in quality of life scores. No significant androgenic effects were noted, BioSante added.
Herjan Coelingh Bennink, Pantarhei's president and chief executive officer, said, 'With these positive clinical results in hand, Pantarhei's current objective is to seek a development partner to move the Pill-Plus concept into Phase III clinical development.'
Copyright RTT News/dpa-AFX
© 2012 AFX News
